Treatment of myositis ossificans progressiva with a diphosphonate.

Treatment of myositis ossificans progressiva with a diphosphonate.

The diphosphonate, disodium etidronate (ethane-1-hydroxy-1,1-diphosphonate, 'EHDP'), a compound known to inhibit the crystal growth of hydroxyapatite and to prevent ectopic calcification in experimental animals, has been given to two women with myositis ossificans progressiva. After remova...

Full description

Bibliographic Details
Main Authors:	Russell, R, Smith, R, Bishop, M, Price, D
Format:	Journal article
Language:	English
Published:	1972

Similar Items

Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment.
by: Smith, R, et al.
Published: (1976)

ACUTE PHASE REACTANTS IN MYOSITIS-OSSIFICANS PROGRESSIVA AND IN ACQUIRED ECTOPIC OSSIFICATION
by: Forster, S, et al.
Published: (1988)

Phenotypic and molecular heterogeneity in fibrodysplasia ossificans progressiva.
by: Virdi, A, et al.
Published: (1999)

Investigation of kinase activation in fibrodysplasia ossificans progressiva
by: Sanvitale, CE
Published: (2014)

Fibrodysplasia ossificans progressiva: Lumps, bumps and biologics
by: Atukorala, I, et al.
Published: (2007)

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva
by: Williams, E, et al.
Published: (2021)

Challenges and opportunities for drug repositioning in Fibrodysplasia ossificans progressiva
by: Ventura, F, et al.
Published: (2021)

Fibrodysplasia ossificans progressiva : current concepts from bench to bedside
by: Kaliya-Perumal, Arun-Kumar, et al.
Published: (2021)

Lymphoblastoid cells in fibrodysplasia ossificans progressiva - Do they play a role?
by: Cohen, T, et al.
Published: (2004)

Paget's disease of bone. Experience with a diphosphonate (disodium etidronate) in treatment.
by: Smith, R, et al.
Published: (1973)

Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients.
by: Petrie, K, et al.
Published: (2009)

Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients.
by: Petrie, K, et al.
Published: (2009)

Diphosphonates in Paget's disease.
by: Russell, R, et al.
Published: (1974)

Diphosphonates and polyphosphates in medicine
by: Russell, R
Published: (1975)

Living with fibrodysplasia ossificans progressiva: radiological images of a patient with extensive heterotopic ossification
by: Mohammed Mostafa Kotb, et al.
Published: (2023)

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
by: Chaikuad, A, et al.
Published: (2012)

Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva
by: Chaikuad, A, et al.
Published: (2012)

An atypical mutation in the activin a receptor, type 1 gene (ACVR1) in a severely affected Fibrodysplasia Ossificans Progressiva patient
by: Petrie, K, et al.
Published: (2007)

Identification of a novel mutation in activin receptor type 1 (ACVR1) in a fibrodysplasia ossificans progressiva (FOP) patient
by: Petrie, K, et al.
Published: (2007)

Development of BMP type I receptor kinase inhibitors for the treatment of fibrodysplasia ossificans progressiva and the study of the BMP signaling pathway
by: Mohedas, Agustin Humberto
Published: (2014)

A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva.
by: Shore, E, et al.
Published: (2006)

Congenital hallux valgus occurs in Fibrodysplasia Ossificans Progressiva and BMPR1B- associated dysplasia: an important distinction
by: Shirodkar, D, et al.
Published: (2024)

Development of macrocycle kinase inhibitors for ALK2 using Fibrodysplasia ossificans progressiva‐derived endothelial cells
by: Sánchez‐Duffhues, G, et al.
Published: (2019)

Response to "Mutations of the NOGGIN and of the activin A type I receptor genes in fibrodysplasia ossificans progressiva (FOP)" by Lucotte et al.
by: Kaplan, F, et al.
Published: (2008)

ABNORMAL BONE FORMATION IN ANKYLOSING SPONDYLITIS: WHAT CAN WE LEARN FROM ACVR1 AND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA?
by: Cain, P, et al.
Published: (2010)

Proceedings: Background to the use of diphosphonates as bone scanning agents.
by: Russell, R, et al.
Published: (1975)

Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
by: Gray, R, et al.
Published: (1987)

Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.
by: Russell, R, et al.
Published: (1975)

Erratum: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva (Nature Genetics (2006) 38, (525-527))
by: Shore, E, et al.
Published: (2007)

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date
by: Gregson, C, et al.
Published: (2011)

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.
by: Gregson, C, et al.
Published: (2011)

A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.
by: Gregson, C, et al.
Published: (2011)

Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
by: Mohedas, A, et al.
Published: (2014)

Inclusion body myositis
by: Hilton-Jones, D
Published: (2002)

Proceedings: Some effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on calcium metabolism in man.
by: Walton, R, et al.
Published: (1974)

Effects of a diphosphonate (disodium etidronate: EHDP) on phosphate metabolism in Paget's disease of bone, primary hyperparathyroidism and type I hypophosphataemic rickets.
by: Walton, R, et al.
Published: (1976)

HLA antigen expression in myositis.
by: Isenberg, D, et al.
Published: (1985)

In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype.
by: Chinoy, H, et al.
Published: (2005)

STUDIES ON HYPERPHOSPHATEMIA INDUCED BY DISODIUM ETHANE-1-HYDROXY-1, 1-DIPHOSPHONATE (EHDP) IN MAN
by: Walton, R, et al.
Published: (1974)

Myositis mimics: how to recognize them.
by: Hilton-Jones, D
Published: (2014)